Central Pharmaceutical Joint Stock Company No3 (HNX:DP3)
Vietnam · Delayed Price · Currency is VND 60,300
-300 (-0.50%)
At close: Nov 3, 2026
HNX:DP3 Financials Overview
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 524,408 | 437,927 | 417,485 | 409,731 | 485,074 | 381,077 |
Revenue Growth | 24.11% | 4.90% | 1.89% | -15.53% | 27.29% | -3.70% |
Gross Profit Gross Profit Growth | 343,057 | 287,582 | 276,054 | 281,503 | 336,538 | 263,630 |
Operating Income Operating Income Growth | 235,250 | 170,252 | 136,682 | 136,885 | 127,821 | 112,139 |
Net Income Net Income Growth | 215,999 | 156,073 | 121,172 | 125,263 | 108,824 | 94,305 |
Earnings Per Share EPS Growth | 10046.49 | 7259.25 | 5635.90 | 5826.22 | 4808.40 | 4386.40 |
EPS Growth | 67.34% | 28.80% | -3.27% | 21.17% | 9.62% | -17.32% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 527,685 | 475,464 | 341,693 | 306,375 | 206,484 | 161,727 |
Total Debt Total Debt Growth | 43,866 | 34,273 | - | 7,775 | 5,230 | 3,528 |
Net Cash (Debt) Net Cash Growth | 483,818 | 441,191 | 341,693 | 298,600 | 201,254 | 158,199 |
Net Cash Growth | 21.42% | 29.12% | 14.43% | 48.37% | 27.21% | 1.71% |
Net Cash Per Share Net Cash Per Share Growth | 22503.24 | 20520.58 | 15892.74 | 13888.41 | 8892.41 | 7358.34 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 109,470 | 151,507 | 91,917 | 153,102 | 99,215 | 26,308 |
Capital Expenditures CapEx Growth | -7,588 | -7,588 | -1,465 | -6,403 | -15,089 | -446.26 |
Free Cash Flow Free Cash Flow Growth | 101,882 | 143,919 | 90,452 | 146,699 | 84,126 | 25,862 |
Free Cash Flow Growth | -49.39% | 59.11% | -38.34% | 74.38% | 225.29% | -52.21% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 65.42% | 65.67% | 66.12% | 68.70% | 69.38% | 69.18% |
Operating Margin | 44.86% | 38.88% | 32.74% | 33.41% | 26.35% | 29.43% |
Pretax Margin | 50.90% | 43.98% | 36.39% | 38.32% | 28.14% | 31.02% |
Profit Margin | 41.19% | 35.64% | 29.02% | 30.57% | 22.43% | 24.75% |
FCF Margin | 19.43% | 32.86% | 21.67% | 35.80% | 17.34% | 6.79% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 3, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 4000.000 | 4000.000 | 3000.000 | 3000.000 | - | 2400.000 |
Dividend Per Share Growth | 33.33% | 33.33% | 0% | - | - | - |
Dividend Yield | 6.63% | 7.58% | 5.15% | 4.58% | - | 5.31% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 3, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 6.00 | 7.27 | 10.34 | 11.24 | 7.43 | 10.31 |
Forward PE | - | 7.61 | - | - | - | - |
P/FCF Ratio | 12.73 | 7.89 | 13.86 | 9.60 | 9.61 | 37.58 |
PS Ratio | 2.47 | 2.59 | 3.00 | 3.44 | 1.67 | 2.55 |